Search
Alclofenac
go.drugbank.com/drugs/DB13167ApprovedWithdrawnAlclofenac is a non-steroidal anti-inflammatory drug. It was withdrawn from the market in the United Kingdom in 1979.
Amifampridine
go.drugbank.com/drugs/DB11640ApprovedIt is currently used as the first-line symptomatic treatment for LEMS in adult patients and is ideally given as oral tablets in divided doses, three or four times a day. … LEMS is a rare auto-immune disorder of the neuromuscular junction that is characterized by proximal muscle weakness, depressed tendon reflexes, and posttetanic potentiation in addition to autonomic dysfunction
Doxepin
go.drugbank.com/drugs/DB01142ApprovedInvestigational[T83] In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline … [L5977] Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant.[L5971] However, in 2010 it was approved for the treatment of insomnia.
Products: DOXEPIN AL 50, DOXEPIN AL 100Imelasomeran
go.drugbank.com/drugs/DB17090ApprovedInvestigational[L45320] It encodes for the viral spike protein of the Omicron BA.1 variant of SARS-CoV-2, a particularly infectious variant of concern first documented in 2021.[L43922] … Imelasomeran was first approved in Canada on September 1, 2022, as one-half of Moderna's Spikevax Bivalent COVID-19 mRNA vaccine.
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. … Iptacopan is a small-molecule factor B inhibitor previously investigated as a potential treatment for the rare blood disease paroxysmal nocturnal hemoglobinuria (PNH) by inhibiting the complement factor
Categories: Compounds used in a research, industrial, or household settingIstradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[A184067] Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. … [L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213]
Fexinidazole
go.drugbank.com/drugs/DB12265Approvedworsening neurological symptoms and eventually die if left untreated. … Transmitted by the bite of an infected tsetse fly, HAT is biphasic with a first (hemolymphatic) stage that progresses to a second (meningoencephalitic) stage in which patients experience progressively
Telaprevir
go.drugbank.com/drugs/DB05521ApprovedWithdrawnHCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. … Telaprevir is an inhibitor of NS3/4A, a serine protease enzyme, encoded by HCV genotype 1 [FDA Label].
Synonyms: (1S,3aR,6aS)-(2S)-2-cyclohexyl-N-(pyrazinylcarbonyl)glycyl-3-methyl-L-valyl-N-((1S)-1-((cyclopropylamino)oxoacetyl)butyl)octahydrocyclopenta(c)pyrrole-1-carboxamideCategories: NS3/4A Protease Inhibitors, HCV NS3/4A Protease InhibitorsPindolol
go.drugbank.com/drugs/DB00960ApprovedInvestigationalPindolol is a first generation non-selective beta blocker used in the treatment of hypertension. … [A231059] Research into pindolol's use in the treatment of hypertension began in the early 1970s.[A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]
International brands: Blockin L, Blocklin LSodium bisulfite
go.drugbank.com/drugs/DB14015ApprovedWithdrawnSodium bisulfite has been used externally for parasitic skin diseases and as a gastrointestinal antiseptic.
Synonyms: Bisulfite de sodiumMixtures: Nephramine Liq IV